India approves AstraZeneca and local Covid vaccines, rollout in weeks

Published January 3, 2021
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters

India’s drugs regulator on Sunday gave final approval for the emergency use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.

The world’s second most populous country is now expected to start a massive immunisation programme within weeks, with the AstraZeneca/Oxford shot taking the lead and Bharat Biotech’s Covaxin administered under stricter conditions given that no efficacy data has been released for it.

The overall efficacy of the AstraZeneca/Oxford vaccine was 70.42 per cent, while Bharat Biotech’s Covaxin was “safe and provides a robust immune response”, said Drugs Controller General of India VG Somani.

The British-developed AstraZeneca/Oxford shot is being made locally by the Serum Institute of India (SII) and will be branded Covishield, while Bharat Biotech has teamed up with the government run Indian Council of Medical Research.

“Vaccines of Serum [Institute of India] and Bharat Biotech are being approved for restricted use in emergency situations,” Somani read out from a written statement at a press conference. Somani did not take questions.

Both vaccines will be administered in two doses and stored at two to eight degrees Celsius, he said. Sources told Reuters on Saturday the doses would have to be given four weeks apart.

Somani explained that the Bharat Biotech vaccine had been approved “in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains”.

Prime Minister Narendra Modi welcomed the approvals.

“It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!” he said on Twitter, calling it a sign of a “self-reliant” country.

SII, the world’s biggest vaccine producer, has already stockpiled more than 50 million doses of the AstraZeneca/Oxford vaccine even without a formal supply deal with the government.

“All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off,” CEO Adar Poonawalla said on Twitter. “Covishield, India’s first Covid-19 vaccine, is approved, safe, effective and ready to roll out in the coming weeks.”

Opinion

Editorial

TTP talks’ oversight
Updated 07 Jul, 2022

TTP talks’ oversight

The bottom line is that the state should not negotiate with terrorists from a position of weakness.
Rain disaster
07 Jul, 2022

Rain disaster

IT is the same story year in and year out. Despite many lives lost, billions of rupees in accumulated damages and ...
Sri Lanka bankruptcy
07 Jul, 2022

Sri Lanka bankruptcy

CRITICALLY low foreign exchange reserves; a plummeting currency and a tanking economy; lengthy power cuts and long,...
Miftah’s misery
Updated 06 Jul, 2022

Miftah’s misery

It cannot be easy to be finance minister in times like these, with friend and foe alike gunning for you over difficult decisions.
Phone tapping
06 Jul, 2022

Phone tapping

IT is the season of audio leaks. No sooner does one ‘incriminating’ clip lose its shock value than another...
Transgender job quota
06 Jul, 2022

Transgender job quota

IN a society where transgender persons often face violence and abuse, the Sindh Assembly’s decision to reserve a...